問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Nephrology

Division of General Internal Medicine

更新時間：2023-09-19

邱怡仁Chiu, I-jen
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 10 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱怡仁

List

21Cases

2022-10-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting11Sites

2021-11-01 - 2026-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-02-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-02-01 - 2022-08-12

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-03-15 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2024-09-30 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2019-01-01 - 2023-06-30

Phase III

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD

  • Condition/Disease

    Iron Deficiency Anemia With Non-Dialysis Dependent CKD

  • Test Drug

    PBF-1681

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2021-07-01 - 2023-02-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2018-03-23 - 2020-04-14

Phase III

A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

  • Condition/Disease

    Secondary Hyperparathyroidism/Hemodialysis

  • Test Drug

    Parsabiv

Participate Sites
13Sites

Terminated13Sites

2021-11-01 - 2026-02-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB